Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response-Reference-Cited by-同舟云学术

Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response

Published:2015-08-06 Issue:9 Volume:17 Page:925-935
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Kao David P.¹,Lewsey James D.²,Anand Inder S.³,Massie Barry M.⁴,Zile Michael R.⁵,Carson Peter E.⁶,McKelvie Robert S.⁷,Komajda Michel⁸,McMurray John JV²,Lindenfeld JoAnn¹

Affiliation:

1. University of Colorado School of Medicine; Aurora CO USA

2. University of Glasgow; Glasgow UK

3. Veterans Affairs Medical Center and University of Minnesota; Minneapolis MN USA

4. University of California San Francisco; San Francisco CA USA

5. Medical University of South Carolina and the RHF Department of Veterans Affairs Medical Center; Charleston SC USA

6. Washington Veterans Affairs Medical Center and Georgetown University; Washington DC USA

7. Population Health Research Institute and McMaster University; Hamilton Ontario Canada

8. University Pierre et Marie Curie Paris VI, La Pitié-Salpétrière Hospital Paris; France

Funder

National Heart, Lung, and Blood Institute

Bristol-Myers Squibb

AstraZeneca

Sanofi

Jacqueline Marie Leaffer Foundation and the University of Colorado Center for Women’s Health Research.

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?;Campbell;J Am Coll Cardiol,2012

2. Irbesartan in patients with heart failure and preserved ejection fraction;Massie;N Engl J Med,2008

3. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial;Yusuf;Lancet,2003

4. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE);Komajda;Circ Heart Fail,2011

5. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial;Haass;Circ Heart Fail,2011

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insuficiencia cardiaca con fracción de eyección preservada: ¿identificamos fenotipos o individualizamos la valoración?;Revista Española de Geriatría y Gerontología;2024-05

2. Socioclinical Phenotyping in Patients With Atherosclerotic Cardiovascular Disease: A Latent Class Analysis;The American Journal of Cardiology;2024-01

3. Unsupervised cluster analysis reveals different phenotypes in patients after transcatheter aortic valve replacement;European Heart Journal Open;2023-12-20

4. Exercise intolerance in heart failure with preserved ejection fraction: Causes, consequences and the journey towards a cure;Experimental Physiology;2023-12-08

5. Device therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction;Heart Failure Reviews;2023-11-08